Related Experiment Videos
nm23-H1 immunoreactivity as a prognostic factor in differentiated thyroid carcinoma
C Zafon1, G Obiols, J Castellví
1Division of Endocrinology, Hospital General i Universitari Vall d'Hebron, Barcelona 08035, Spain.
The Journal of Clinical Endocrinology and Metabolism
|August 15, 2001
Summary
nm23-H1 expression, a gene suppressing metastasis, shows promise as a prognostic factor for differentiated thyroid carcinoma. Its reduced expression is linked to poorer outcomes, especially in follicular thyroid carcinoma patients.
Area of Science:
- Oncology
- Pathology
- Molecular Biology
Background:
- Identifying prognostic factors for differentiated thyroid carcinoma (DTC) metastasis is crucial.
- nm23-H1, a metastatic suppressor gene, has shown controversial results in DTC prognosis.
Purpose of the Study:
- To evaluate the relationship between nm23-H1 expression and clinical status/patient outcome in DTC.
- To determine the utility of nm23-H1 as a prognostic factor in differentiated thyroid carcinoma.
Main Methods:
- Immunohistochemical staining for nm23-H1 in 94 DTC patient specimens (64 papillary, 30 follicular).
- Analysis of nm23-H1 immunoreactivity against clinical data and patient outcomes with at least 5-year follow-up.
Main Results:
- No significant association between nm23-H1 and prognosis in papillary thyroid carcinoma.
- Significant inverse association between nm23-H1 expression and metastatic disease in follicular thyroid carcinoma (P < 0.05).
- nm23-H1 immunoreactivity correlated with survival curves (log-rank P < 0.01) and was more specific than AMES score for predicting metastasis.
Conclusions:
- nm23-H1 immunostaining is a potential prognostic factor for follicular thyroid carcinoma.
- nm23-H1 could complement existing prognostic factors for predicting differentiated thyroid carcinoma outcomes.